We Can’t Have It All: Low Prices, Local Supply, and Fast Access — We Have to Choose

Across the pharmaceutical industry, there is a growing tension that most people inside the system recognize, even if it is rarely stated so directly. The cost of developing new medicines keeps increasing, while at the same time governments and payers continue to push prices downward. Each objective makes sense on its own. Everyone wants innovation to continue, and everyone wants medicines to remain affordable. But taken together, these two forces create a structural imbalance that cannot be fully resolved.

The key misunderstanding is often about what is actually becoming more expensive. It is not only the cost of producing a pill, an injection, or even a complex biologic. The real driver is also research and development. Modern drug development involves long timelines, large and global clinical trials, stricter regulatory requirements, and a high rate of failure. Many projects never reach the market. The cost of the few successful medicines includes the cost of all the ones that did not succeed.

At the same time, pricing pressure is increasing, particularly in Europe, where public healthcare systems are under budget constraints and political pressure. Institutions like the European Commission promote reforms aimed at improving affordability and equal access across member states. One of the key mechanisms used is International Reference Pricing, which links medicine prices across countries. In practice, this means that a low price in one country can influence or pull down prices in others. This creates a system where pricing decisions in one market are never purely local anymore.

When you combine rising R&D costs with downward pressure on prices, companies cannot simply accept lower margins without adjusting their behavior. They respond in ways that are economically rational but sometimes uncomfortable from a policy perspective. Large pharmaceutical companies tend to become more selective. They focus increasingly on therapeutic areas where both medical value and pricing sustainability are higher, such as oncology, rare diseases, and advanced biologics. Other areas, even if medically important, may receive less investment over time.

Another response is geographical selectivity. Because pricing in one country can influence prices elsewhere, companies may delay launching new medicines in lower-price markets or limit their initial availability. This is not necessarily a question of willingness, but of system design. When prices are tightly connected across borders, local pricing decisions have global consequences.

Internally, companies also adjust by restructuring their operations. They may reduce costs, reorganize research pipelines, or in some cases reduce workforce size. These adjustments are often described as efficiency measures, but they are also a reflection of sustained pressure on returns. The same dynamic affects smaller biotechnology firms even more strongly. Without diversified product portfolios, they are more exposed to funding cycles and clinical trial outcomes. As a result, consolidation becomes more common, with larger companies acquiring smaller innovators rather than all innovation being developed internally.

Over time, this leads to a quieter but important structural shift in the market. Medicine development increasingly concentrates in areas where high investment can still be justified, while the middle ground becomes harder to sustain. This is not a planned outcome, but an emergent one.

Policy responses are aware of these issues. Recent reforms try to improve efficiency, speed up approvals, and encourage companies to launch in more countries. The goal is to improve access without increasing costs too much. But these measures tend to work at the edges of the system. They do not fundamentally change the underlying equation, which is that innovation is becoming more expensive, while prices are politically and economically constrained.

This brings us to the central reality that is often avoided in public discussion. Healthcare systems want four things at the same time: low prices, fast and equal access across countries, strong local supply chains, and continuous innovation. Each of these goals is reasonable. Each is politically attractive. But in practice, they compete with each other. Strengthening one usually puts pressure on at least one of the others.

If prices are kept very low, companies may delay launches or reduce investment in certain areas. If local production and supply resilience are prioritized, costs tend to increase. If innovation is strongly incentivized, then higher returns somewhere in the system are usually necessary. There is no configuration where all four objectives are fully maximized at once.

What makes the situation more complex is that these trade-offs are not evenly distributed. Some countries can pay more. Others cannot. Some therapeutic areas attract investment more easily than others. And some patients benefit earlier than others, depending on where they live and how attractive their market is for launch decisions. The system still functions, but not symmetrically.

In practice, the industry is not collapsing under this tension. It is adapting to it. Companies become more strategic, governments refine their policies, and access gradually improves in some areas while remaining uneven in others. But the underlying trade-off remains unchanged.

The uncomfortable truth is that there is no purely technical solution to this. It is not only a question of efficiency or better regulation. It is a question of distribution: who pays, when they pay, and for what level of access and innovation. Until that is addressed more directly, the system will continue to balance competing objectives without fully satisfying all of them.

In the end, the situation is less about failure and more about limits. The system is doing what systems do under constraint: it adjusts, it compromises, and it redistributes pressure. But the fundamental trade-off remains. You can improve outcomes in one direction, but not in all directions at once. And that is the reality the industry is increasingly learning to live with, even if it is rarely said out loud.